Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

Simple item page
dc.contributor.authorNettelbeck, Dirk M.
dc.contributor.authorLeber, Mathias F.
dc.contributor.authorAltomonte, Jennifer
dc.contributor.authorAngelova, Assia
dc.contributor.authorBeil, Julia
dc.contributor.authorBerchtold, Susanne
dc.contributor.authorDelic, Maike
dc.contributor.authorEberle, Jürgen
dc.contributor.authorEhrhardt, Anja
dc.contributor.authorEngeland, Christine E.
dc.contributor.authorFechner, Henry
dc.contributor.authorGeletneky, Karsten
dc.contributor.authorGoepfert, Katrin
dc.contributor.authorHolm, Per Sonne
dc.contributor.authorKochanek, Stefan
dc.contributor.authorKreppel, Florian
dc.contributor.authorKrutzke, Lea
dc.contributor.authorKühnel, Florian
dc.contributor.authorLang, Karl Sebastian
dc.contributor.authorMarchini, Antonio
dc.contributor.authorMoehler, Markus
dc.contributor.authorMühlebach, Michael D.
dc.contributor.authorNaumann, Ulrike
dc.contributor.authorNawroth, Roman
dc.contributor.authorNüesch, Jürg
dc.contributor.authorRommelaere, Jean
dc.contributor.authorLauer, Ulrich M.
dc.contributor.authorUngerechts, Guy
dc.date.accessioned2021-08-17T11:12:50Z
dc.date.available2021-08-17T11:12:50Z
dc.date.issued2021-07-21
dc.date.updated2021-08-01T17:44:32Z
dc.description.abstractVirotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction of anti-tumor immune responses. Oncolytic viruses can also be engineered to genetically deliver therapeutic proteins for direct or indirect cancer cell killing. In this review—as part of the special edition on “State-of-the-Art Viral Vector Gene Therapy in Germany”—the German community of virotherapists provides an overview of their recent research activities that cover endeavors from screening and engineering viruses as oncolytic cancer therapeutics to their clinical translation in investigator-initiated and sponsored multi-center trials. Preclinical research explores multiple viral platforms, including new isolates, serotypes, or fitness mutants, and pursues unique approaches to engineer them towards increased safety, shielded or targeted delivery, selective or enhanced replication, improved immune activation, delivery of therapeutic proteins or RNA, and redirecting antiviral immunity for cancer cell killing. Moreover, several oncolytic virus-based combination therapies are under investigation. Clinical trials in Germany explore the safety and potency of virotherapeutics based on parvo-, vaccinia, herpes, measles, reo-, adeno-, vesicular stomatitis, and coxsackie viruses, including viruses encoding therapeutic proteins or combinations with immune checkpoint inhibitors. These research advances represent exciting vantage points for future endeavors of the German virotherapy community collectively aimed at the implementation of effective virotherapeutics in clinical oncology.en
dc.description.sponsorshipDFG, 68647618, SFB 824: Bildgebung zur Selektion, Überwachung und Individualisierung der Krebstherapieen
dc.description.sponsorshipEC/H2020/853433/EU/A multifaceted cancer immunotherapy based on an immune checkpoint-modulating chimeric oncolytic virus vector in combination with a dendritic cell vaccine/ONCO-VAXen
dc.identifier.eissn1999-4915
dc.identifier.urihttps://depositonce.tu-berlin.de/handle/11303/13511
dc.identifier.urihttp://dx.doi.org/10.14279/depositonce-12294
dc.language.isoenen
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subject.ddc570 Biowissenschaften; Biologiede
dc.subject.otheroncolytic virusen
dc.subject.othervirotherapyen
dc.subject.otherresearch in Germanyen
dc.subject.othervirus engineeringen
dc.subject.othervirus targetingen
dc.subject.othertherapeutic transgeneen
dc.subject.otherimmunotherapyen
dc.subject.othercombination therapyen
dc.subject.otherclinical trialsen
dc.titleVirotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studiesen
dc.typeArticleen
dc.type.versionpublishedVersionen
dcterms.bibliographicCitation.articlenumber1420en
dcterms.bibliographicCitation.doi10.3390/v13081420en
dcterms.bibliographicCitation.issue8en
dcterms.bibliographicCitation.journaltitleVirusesen
dcterms.bibliographicCitation.originalpublishernameMDPIen
dcterms.bibliographicCitation.originalpublisherplaceBaselen
dcterms.bibliographicCitation.volume13en
tub.accessrights.dnbfreeen
tub.affiliationFak. 3 Prozesswissenschaften::Inst. Biotechnologie::FG Angewandte Biochemiede
tub.affiliation.facultyFak. 3 Prozesswissenschaftende
tub.affiliation.groupFG Angewandte Biochemiede
tub.affiliation.instituteInst. Biotechnologiede
tub.publisher.universityorinstitutionTechnische Universität Berlinen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
viruses-13-01420-v3.pdf
Size:
1.51 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.9 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Publications